Application of nalmefene (NALMEFENE), naltrexone (naltrexone) and its related derivatives for the treatment of (non) alcoholic steatohepatitis or nonalcoholic fatty liver disease

• 1. 纳美芬(NALMEFENE)、纳曲酮(NALTREXONE)或其衍生物在治疗(非)酒精性脂肪肝炎(NASH)或非酒精性脂肪性肝病(NAFLD)的应用 [P] . 中国专利： CN109069503A . 2018-12-21
• 2. 从纳曲酮制备盐酸纳美芬 [P] . 中国专利： CN102459276B . 2016.09.21
• 3. Nalmefene, naltrexone or derivatives thereof for use in the treatment of (non) alcoholic fatty liver disease or nonalcoholic fatty liver disease [P] . 韩国专利： KR20180129909A . 2018-12-05

  机译： 纳美芬，纳曲酮或其衍生物，用于治疗（非）酒精性脂肪肝或非酒精性脂肪肝

• 4. Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease [P] . AU2017253228B2 . 2020-04-09

  机译： 纳美芬，纳曲酮或其衍生物，用于治疗（非）酒精性脂肪性肝炎或非酒精性脂肪肝

• 5. Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease [P] . AU2017253228A8 . 2019-01-17

  机译： 纳美芬，纳曲酮或其衍生物，用于治疗（非）酒精性脂肪性肝炎或非酒精性脂肪肝

• 1. Effects of Naltrexone and Nalmefene on Subjective Response to Alcohol Among Non-Treatment-Seeking Alcoholics and Social Drinkers. [J] . Voronin K Alcoholism: Clinical and experimental research . 2004,第9期
• 2. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver diseaseonalcoholic steatohepatitis [J] . Tilg Herbert, Moschen Alexander R., Szabo Gyongyi Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第3期
• 3. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis [J] . Spengler Erin K., Loomba Rohit Mayo Clinic Proceedings . 2015,第9期
• 4. A Deep Learning Approach for Classifying Nonalcoholic Steatohepatitis Patients from Nonalcoholic Fatty Liver Disease Patients Using Electronic Medical Records [C] . Pradyumna Byappanahalli Suresha, Yunlong Wang, Cao Xiao, Health Intelligence Workshop;Association for the Advancement of Artificial Intelligence Annual Conference . 2020
• 5. Metabolic syndrome in non-alcoholic fatty liver disease: A comparison between simple steatosis and non-alcoholic steatohepatitis [D] . Avand, Ghazal 2006
• 6. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis [O] . Chanbin Lee, Jieun Kim, Youngmi Jung 2019
• 7. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis [O] . Herbert Tilg, Alexander R. Moschen, Gyongyi Szabo 2016

• 1. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis [J] . Carla Melisa Chackelevicius ,Sabrina Eliana Gambaro ,Claudio Tiribelli . 世界胃肠病学杂志：英文版 . 2016,第41期
• 2. WJH 6^(th) Anniversary Special Issues(7): Nonalcoholic fatty liver disease Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease [J] . Hye-jin Yoon ,Bong Soo Cha . 世界肝病学杂志：英文版（电子版） . 2014,第11期
• 3. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis [J] . Yoshio Sumida ,Atsushi Nakajima ,Yoshito Itoh . 世界胃肠病学杂志：英文版 . 2014,第2期
• 4. Fractionation of gamma-glutamyltransferase in patients with nonalcoholic fatty liver disease and alcoholic liver disease [J] . Shigeo Sueyoshi ,Setsu Sawai ,Mamoru Satoh . 世界肝病学杂志：英文版（电子版） . 2016,第36期
• 5. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease [J] . Nobuyuki Toshikuni ,Mikihiro Tsutsumi ,Tomiyasu Arisawa . 世界胃肠病学杂志：英文版 . 2014,第26期
• 6. 纳洛酮联合醒脑静与纳美芬联合醒脑静在脑血管病意识障碍患者治疗中的疗效对比 [C] . 张晓杰 ,张琳 ,韩晓芳 . 2015临床急重症经验交流高峰论坛 . 2015
• 7. 酮咯酸联合小剂量纳美芬预防瑞芬太尼术后痛觉过敏的效果观察 [A] . 谢晓雨 . 2021